reboxetine has been researched along with Parkinsonian Disorders in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagińska, M; Barut, J; Chmielarz, P; Daniel, WA; Kot, M; Kreiner, G; Nalepa, I; Parlato, R; Rafa-Zabłocka, K | 1 |
1 other study(ies) available for reboxetine and Parkinsonian Disorders
| Article | Year |
|---|---|
Stimulation of noradrenergic transmission by reboxetine is beneficial for a mouse model of progressive parkinsonism.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopaminergic Neurons; Female; Imidazoles; Immunohistochemistry; Locus Coeruleus; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Reboxetine; Substantia Nigra; Ventral Tegmental Area | 2019 |